⚠️ Neutral
Listed
Healthcare Services
Molbio Diagnostics Limited IPO
₹940 Cr · Fresh Issue & OFS · Healthcare Services
Price Band
₹768 – ₹807
GMP (Grey Market)
—
No GMP data yet
Issue Size
₹940 Cr
Fresh Issue & OFS
Market Cap
₹9299.87 Cr
At upper band
P/E Ratio
56.7x
P/S: 6.4x
Listing Date
17 Aug 2026
BSE & NSE
IPO Timeline
✓
Opens
10 Aug 2026
✓
Closes
12 Aug 2026
✓
Allotment
13 Aug 2026
✓
Refund
14 Aug 2026
✓
Listing
17 Aug 2026
IPO India Hub: Neutral
Conviction
5/10
The company shows strong revenue growth (31.6% CAGR) and exceptional PAT expansion (40.2% CAGR), but valuation at 1.42× sector midpoint combined with a 78.7% OFS component and promoter dilution to 41.29% post-issue create offsetting headwinds. Margin quality at 11.4% NPM is below the 15% threshold that would justify premium pricing.
Listing Performance
Issue Price
₹807
Allotment price
Listing Price
₹980
+21.44% on listing day
Current Price (CMP)
₹1441.6
+78.6% vs issue
Listed On
17 Aug 2026
BSE & NSE
Our Analysis — Key Points
✓ Strength
Exceptional profit growth trajectory
Net profit has grown at 40.2% CAGR over two years (₹83.5 Cr to ₹164.1 Cr), significantly outpacing revenue growth of 31.6%. This demonstrates operating leverage and improving unit economics in the diagnostics business.
✓ Strength
Strong operational efficiency metrics
EBITDA margin of 24.97% and ROCE of 20.98% indicate efficient capital deployment and healthy cash generation. These metrics support the company's ability to fund capex for R&D and manufacturing expansion without excessive leverage.
⚠ Risk
Massive OFS dilutes growth narrative
78.7% of the ₹940 Cr issue is OFS (secondary sale), meaning only ~₹200 Cr flows to the company for capex. This severely limits the capital available for stated growth initiatives in R&D and Goa facility expansion, undermining the IPO's stated purpose.
⚠ Risk
Promoter stake erosion post-listing
Promoter holding falls from 44.89% pre-issue to 41.29% post-issue, signaling material dilution. Combined with 78.7% OFS, this raises questions about promoter conviction and future governance control in a founder-led diagnostics business.
₹ Valuation
Valuation at sector midpoint with margin caveat
P/E of 56.7× translates to 1.42× the 40× healthcare sector midpoint—technically within Subscribe range. However, NPM of 11.4% falls short of the 15% threshold that would justify premium pricing, placing the company at fair value rather than a discount.
👁 Watch
Monitor capex execution and cash burn
With only ~₹200 Cr of fresh capital inflow, track whether the company can deliver the stated R&D and Goa facility projects on time and within budget, or if it must rely on internal cash generation or debt.
Top Analyst Reviews
| Analyst / Firm | Rating | Known For | Review |
|---|---|---|---|
| IPO India Hub Our independent review |
Original analysis based on DRHP & public financials | This page | |
| Dilip Davda Chittorgarh.com |
India's most followed independent IPO analyst | Search on Chittorgarh → | |
| Capital Market (CM Rating) CapitalMarket.com |
Widely-cited "New Issue Monitor" reports | Search on CapitalMarket → | |
| ICICI Securities ICICIdirect Research |
SEBI-registered broker research desk | Visit ICICIdirect → | |
| IPO Guru Analyst Leaderboard ipoguru.in |
Ranks 49 analysts by real IPO outcome accuracy | View leaderboard → |
External links go to each platform's IPO section — search for "Molbio Diagnostics Limited" to find the specific review. IPO India Hub does not represent the accuracy of third-party ratings.
Company Snapshot
Revenue
₹1445.69 Cr
Net Profit
₹164.14 Cr
Industry
Healthcare Services
Issue Type
Fresh Issue & OFS
Promoters
SRIRAM NATARAJAN, DR. CHANDRASEKHAR BHASKARAN NAIR, SANGEETHA SRIRAM, SHIVA SRIRAM, SOWMYA SRIRAM AND EXXORA TRADING LLP
Lead Managers
Kotak Mahindra Capital, IIFL Capital, Jefferies and Motilal Oswal Investment Advisory
Quick Actions
Frequently Asked Questions
Neutral. The company shows strong revenue growth (31.6% CAGR) and exceptional PAT expansion (40.2% CAGR), but valuation at 1.42× sector midpoint combined with a 78.7% OFS component and promoter dilution to 41.29% post-issue create offsetting headwinds. Margin quality at 11.4% NPM is below the 15% threshold that would justify premium pricing.
GMP data is not yet available for this IPO. Check our GMP Live page for the latest updates closer to the listing date.
Lot size details will be updated when the DRHP is filed. The price band is ₹768 – ₹807.
The IPO opens on 10 Aug 2026. It closes on 12 Aug 2026. Allotment is expected on 13 Aug 2026. Refunds initiate on 14 Aug 2026. Listing on BSE and NSE is on 17 Aug 2026.
The lead managers for the IPO are Kotak Mahindra Capital, IIFL Capital, Jefferies and Motilal Oswal Investment Advisory. Check the SEBI filing for the registrar details.
The IPO listed on 17 Aug 2026 at ₹980 against an issue price of ₹807 (+21.44% on listing day). The current market price (CMP) is approximately ₹1441.6 (+78.6% vs issue).
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 12 Aug 2026. The company shows strong revenue growth (31.6% CAGR) and exceptional PAT expansion (40.2% CAGR), but valuation at 1.42× sector midpoint combined with a 78.7% OFS component and promoter dilution to 41.29% post-issue create offsetting headwinds. Margin quality at 11.4% NPM is below the 15% threshold that would justify premium pricing.
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 12 Aug 2026. The IPO is priced at a P/E of 56.7x. Market cap at issue price is ₹9299.87 Cr. As with all IPOs, please read the DRHP and assess your own risk tolerance before investing.
You can apply via UPI through your broker's trading app (Zerodha, Upstox, Fyers, etc.) or via ASBA through your net banking portal. The issue closes on 12 Aug 2026, so apply before that date. Step 1: Log in to your broker or bank app. Step 2: Go to IPO section and search for 'Molbio Diagnostics Limited'. Step 3: Enter the number of lots and UPI ID. Step 4: Accept the mandate on your UPI app.
Explore More